While Avastin is designed to treat cancer, not blindness, many doctors say it works just as well as Lucentis — with significant potential cost savings to patients, insurers, and the government.

One of the many concerns about President Obama’s health care legislation is that it will encourage—if not eventually require—the government to approve the cheapest rather than the best ...

"[W]e found that the majority of physicians who administered Avastin to treat wet AMD reported the substantial cost difference compared to Lucentis as a primary factor in their decision," OIG ...

Avastin, the anti-cancer drug already widely used off-label by physicians to treat the wet form of age-related macular degeneration, is as effective as Lucentis, the gold standard for treatment of ...

Researchers say switching patients from Lucentis to Avastin eye diseases could save the government $18 billion. Deborah Weinstein June 3, 2014 5:30 pm Study: Using Avastin over Lucentis could save ...

In 2004, the FDA approved Avastin for the systemic treatment of metastatic colon cancer. Genentech later developed Lucentis, derived from a protein similar to Avastin, specifically for injection ...

Avastin and Lucentis: two drugs with roughly the same molecular structure, both manufactured by the same drugmaker. One is approved to treat cancer, the other wet age-related macular degeneration.

I’m a doctor with a miracle drug. Three of them, in fact. Their names are Avastin, Lucentis and Eylea. I use them to treat the No. 1 cause of blindness in Americans over 65: wet age-related ...

That's when the National Institutes of Health will release the initial results of a National Eye Institute head-to-head study of the drugs Lucentis and Avastin as treatments for an eye condition ...

More fuel for the Avastin-vs-Lucentis debate: A big U.S. government study of the two drugs deemed them more or less equivalent for treating age-related macular degeneration. It's a finding that ...

Full publication of results from the head-to-head study of Avastin (bevacizumab) and Lucentis (ranibizumab) in "wet" age-related macular degeneration (AMD) confirmed information previously leaked ...

The valuation of Genentech shares is "less attractive," said SG Cowen, as blockbuster cancer drug Avastin could limit the potential of the biotech firm's promising blindness treatment, Lucentis.